Presentations collectively highlight pilavapadin’s potential to improve pain management care for patients with diabetic peripheral neuropathic pain (DPNP) Breadth of the data across Phase 2 program to be discussed at Arrowhead’s 19th Annual Pain Summit THE WOODLANDS, Texas, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the presentation of clinical data for its investigational, AAK1-inhibitor, pilavapadin, for the treatment of diabetic peripheral neuropathic ...

Lexicon Pharmaceuticals (NasdaqGS:LXRX) FY Conference September 08, 2025 02:30 PM ET Company ParticipantsLander Egaña-Gorroño - Senior Associate - Biotech Equity ResearchMike Exton - CEO & DirectorConference Call ParticipantsNone - AnalystLander Egaña-GorroñoEveryone, my name is Lander. I'm a Senior Research Associate at H.C. Wainwright. We're pleased to have you with us today, and it is now my pleasure to introduce our next presenter. Please join me in welcoming Mike Exton, CEO of Lexicon Pharmaceuticals, ...

Data obtained from ongoing third-party funded, investigator-sponsored trials have been submitted in effort to address the December 2024 complete response letter Company seeks alignment on reasonable path forward for Zynquista NDA resubmission FDA feedback from Type D meeting expected by end of September THE WOODLANDS, Texas, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the Company has submitted additional clinical data to the U.S. Food and Drug Adminis ...

THE WOODLANDS, Texas, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the Company will present new data demonstrating the reduction of neuropathic pain by pilavapadin in preclinical models of chemotherapy-induced peripheral neuropathy (CIPN) and multiple sclerosis (MS) at the 9th International Congress on Neuropathic Pain - (NeuPSIG) 2025. The findings highlight the relevance of inhibiting pilavapadin’s novel target, AAK1, for the modulation of pain signa ...

Question-and-Answer SessionMichael ExtonCEO & Director Yes. No, absolutely. It's been a busy 2/3 of the year. And now that the kids are back at school, it's going to be a very busy back third, I'd say. So yes, look, it's been a very interesting year for us as we started the year pivoting back towards a pure R&D company to focus on the pipeline. And as a result of that, we've made great progress, I believe, across the main 3 assets that we have in the pipeline. And taking them somewhat chronologically, we -- ...

Lexicon Pharmaceuticals (LXRX) Conference Summary Company Overview - **Company**: Lexicon Pharmaceuticals (LXRX) - **Date of Conference**: September 03, 2025 - **Key Speakers**: Mike Exton (CEO), Craig Granowitz (CMO) Key Points and Arguments Company Evolution and Pipeline Focus - Lexicon Pharmaceuticals has shifted back to a pure R&D focus, emphasizing its pipeline development [4][5] - The company has made significant progress with three main assets in its pipeline [4] Licensing and Collaborations - In Q1 2025, Lexicon licensed LX9851, a preclinical asset for obesity, to Novo Nordisk, a leader in obesity treatment [4] Clinical Trials and Data - The PROGRESS Phase 2b study for pilovapitan, a non-opioid treatment for diabetic peripheral neuropathic pain, has shown promising results, with plans to move into Phase 3 trials in early 2026 [5][6] - The company is preparing for a busy September with multiple data rollouts at medical meetings [6] Heart Failure and HCM Programs - Lexicon continues to market sotagliflozin for heart failure under PEPFAR, maintaining sales levels from the previous year [6] - The SONARDA trial for hypertrophic cardiomyopathy (HCM) is progressing well, with full patient enrollment expected by 2026 [7] Data Analysis and Findings - A pooled analysis of over 12,000 patients in heart failure studies showed consistent responses across age groups, particularly in elderly patients [10] - The analysis indicated a 50% reduction in hospital readmissions and cardiovascular death at various time points, highlighting the efficacy of sotagliflozin compared to other SGLT inhibitors [12][14] Differentiation in Treatment - Lexicon's approach to treating HFpEF and non-obstructive HCM is unique, as sotagliflozin addresses underlying metabolic disorders in the myocardium [29] - The company aims to position sotagliflozin as the first-line treatment for both HFpEF and HCM, leveraging its efficacy and safety profile [35] Trial Design and Regulatory Engagement - The SONARDA trial is designed to include both obstructive and non-obstructive HCM patients, with a primary endpoint focused on symptom relief [40] - Lexicon is in discussions with the FDA to finalize the design for Phase 3 trials, aiming for a straightforward approval process based on previous Phase 2 data [62][66] Financial and Partnership Strategy - Lexicon plans to partner for the Phase 3 program, seeking a partner that is committed to long-term investment in the drug's development [78] - The company is exploring various partnership structures, aiming for a worldwide deal [79] Upcoming Events - The Arrowhead meeting in October will feature data presentations across Lexicon's Phase 2 programs, which are expected to inform the end of Phase 2 meeting with the FDA [81] Additional Important Insights - The analysis of the MAPLE trial indicated that beta blockers may cause harm, suggesting a potential shift in treatment paradigms for HCM [34] - The company is focused on simplifying trial designs to reduce variability and enhance the clarity of results [68] This summary encapsulates the key discussions and insights from the Lexicon Pharmaceuticals conference, highlighting the company's strategic focus on R&D, clinical advancements, and market positioning in the biopharmaceutical landscape.

THE WOODLANDS, Texas, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced data from a study of patients describing the physical and psychological impact of diabetic peripheral neuropathic pain (DPNP), despite treatment with available over-the-counter and prescription pain relievers will be presented at PAINWeek 2025. The conference is being held September 2-4, 2025, at The Cosmopolitan in Las Vegas, Nevada. Presentation details: Poster #53: Listening to Patients w ...

Core Insights - Lexicon Pharmaceuticals presented a post-hoc analysis of sotagliflozin's efficacy among older adults at the ESC 2025 Congress, highlighting improvements in heart failure endpoints and major adverse cardiovascular events (MACE) [1][2][3] Company Overview - Lexicon Pharmaceuticals is a biopharmaceutical company focused on pioneering medicines that transform patients' lives, utilizing its Genome5000™ program for genomics target discovery [8] Study Details - The analysis pooled data from two pivotal Phase 3 studies, SCORED and SOLOIST-WHF, involving nearly 12,000 participants, with approximately 70% aged 65 or older [2][4] - The primary endpoint was total cardiovascular death, hospitalization for heart failure, or urgent visits for heart failure, with additional endpoints including total MACE [2] Efficacy Results - Sotagliflozin reduced the primary endpoint rate compared to placebo: 8.5 vs 11.8 events per 100 person-years (HR: 0.72) overall, and 8.9 vs 12.4 events per 100 person-years (HR: 0.73) for those aged 65 and older [5] - Total MACE was similarly reduced with sotagliflozin: 5.7 vs 7.1 events per 100 person-years (HR: 0.80) overall, and 5.9 vs 7.4 events per 100 person-years (HR: 0.80) for those aged 65 and older [6] Future Research Directions - Future research may focus on the benefits of sotagliflozin in heart failure patients with preserved ejection fraction (HFpEF), a demographic that is generally older and includes more women [3]

THE WOODLANDS, Texas, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at Citi's Biopharma Back to School Conference on Wednesday, September 3 at 1:45 p.m. ET and at the H.C. Wainwright 27th Annual Global Investment Conference on Monday, September 8 at 3:00 p.m. ET. The live events and replays of the presentations can be accessed via the Events page of the Company’s website at https://investors.lexpharm ...

Core Viewpoint - Lexicon Pharmaceuticals (LXRX) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][4]. Earnings Estimates and Ratings - The Zacks rating system is primarily driven by changes in a company's earnings picture, with the Zacks Consensus Estimate tracking EPS estimates from sell-side analysts [2]. - The recent upgrade reflects an improvement in Lexicon's earnings outlook, which could lead to increased buying pressure and a rise in stock price [4][6]. Impact of Earnings Estimate Revisions - Changes in future earnings potential, as indicated by earnings estimate revisions, are strongly correlated with near-term stock price movements [5][7]. - Institutional investors utilize earnings estimates to determine the fair value of stocks, influencing their buying and selling actions, which subsequently affects stock prices [5]. Lexicon's Earnings Outlook - For the fiscal year ending December 2025, Lexicon is expected to earn -$0.28 per share, unchanged from the previous year, but the Zacks Consensus Estimate has increased by 24.8% over the past three months [9]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have generated an average annual return of +25% since 1988 [8]. - Lexicon's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10][11].